These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 33758897)

  • 1. Anti-SARS-CoV-2 Serology persistence over time in COVID-19 Convalescent Plasma Donors.
    De Giorgi V; West KA; Henning AN; Chen L; Holbrook MR; Gross R; Liang J; Postnikova E; Trenbeath J; Pogue S; Scinto T; Alter HJ; Cantilena CC
    medRxiv; 2021 Mar; ():. PubMed ID: 33758897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies.
    Körper S; Jahrsdörfer B; Corman VM; Pilch J; Wuchter P; Blasczyk R; Müller R; Tonn T; Bakchoul T; Schäfer R; Juhl D; Schwarz T; Gödecke N; Burkhardt T; Schmidt M; Appl T; Eichler H; Klüter H; Drosten C; Seifried E; Schrezenmeier H
    Transfus Med Hemother; 2021 May; 48(3):137-147. PubMed ID: 34177417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naturally Acquired SARS-CoV-2 Immunity Persists for Up to 11 Months Following Infection.
    De Giorgi V; West KA; Henning AN; Chen LN; Holbrook MR; Gross R; Liang J; Postnikova E; Trenbeath J; Pogue S; Scinto T; Alter HJ; Cantilena CC
    J Infect Dis; 2021 Oct; 224(8):1294-1304. PubMed ID: 34089610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
    Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
    Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seroprevalence of SARS-CoV-2 among potential convalescent plasma donors and analysis of their deferral pattern: Experience from tertiary care hospital in western India.
    Jain R; Mallya MV; Amoncar S; Palyekar S; Adsul HP; Kumar R; Chawla S
    Transfus Clin Biol; 2022 Feb; 29(1):60-64. PubMed ID: 34302953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of COVID-19 Seropositive Plasma as Convalescent Plasma: An Immune and Neutralization Antibody Seroprevalence Analysis in Blood Donors for Future Potential Pandemic Readiness.
    Jain A; Negi G; Kaur D; S V; Saxena V
    Cureus; 2024 Mar; 16(3):e57149. PubMed ID: 38681329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A longitudinal study of convalescent plasma (CCP) donors and correlation of ABO group, initial neutralizing antibodies (nAb), and body mass index (BMI) with nAb and anti-nucleocapsid (NP) SARS-CoV-2 antibody kinetics: Proposals for better quality of CCP collections.
    Wendel S; Fontão-Wendel R; Fachini R; Candelaria G; Scuracchio P; Achkar R; Brito M; Reis LF; Camargo A; Amano M; Machado R; Araujo D; Soares C; Durigon E
    Transfusion; 2021 May; 61(5):1447-1460. PubMed ID: 33604884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of 52 240 source plasma donors of convalescent COVID-19 plasma: Sex, ethnicity, and age association with initial antibody levels and rate of dissipation.
    Schmidt AE; Vogel P; Chastain CA; Barnes T; Roth NJ; Simon TL
    J Clin Apher; 2022 Oct; 37(5):449-459. PubMed ID: 35815776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study.
    Terpos E; Politou M; Sergentanis TN; Mentis A; Rosati M; Stellas D; Bear J; Hu X; Felber BK; Pappa V; Pagoni M; Grouzi E; Labropoulou S; Charitaki I; Ntanasis-Stathopoulos I; Moschandreou D; Bouhla A; Saridakis S; Korompoki E; Giatra C; Bagratuni T; Pefanis A; Papageorgiou S; Spyridonidis A; Antoniadou A; Kotanidou A; Syrigos K; Stamoulis K; Panayiotakopoulos G; Tsiodras S; Alexopoulos L; Dimopoulos MA; Pavlakis GN
    Microorganisms; 2020 Nov; 8(12):. PubMed ID: 33260775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects.
    Achiron A; Gurevich M; Falb R; Dreyer-Alster S; Sonis P; Mandel M
    Clin Microbiol Infect; 2021 Sep; 27(9):1349.e1-1349.e6. PubMed ID: 33975009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort.
    Zhang S; Xu K; Li C; Zhou L; Kong X; Peng J; Zhu F; Bao C; Jin H; Gao Q; Zhao X; Zhu L
    Front Immunol; 2022; 13():829665. PubMed ID: 35154152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
    Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
    EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers.
    Patel EU; Bloch EM; Clarke W; Hsieh YH; Boon D; Eby Y; Fernandez RE; Baker OR; Keruly M; Kirby CS; Klock E; Littlefield K; Miller J; Schmidt HA; Sullivan P; Piwowar-Manning E; Shrestha R; Redd AD; Rothman RE; Sullivan D; Shoham S; Casadevall A; Quinn TC; Pekosz A; Tobian AAR; Laeyendecker O
    J Clin Microbiol; 2021 Jan; 59(2):. PubMed ID: 33139419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Three Quantitative Anti-SARS-CoV-2 Antibody Immunoassays.
    Chapuy-Regaud S; Miédougé M; Abravanel F; Da Silva I; Porcheron M; Fillaux J; Diméglio C; Izopet J
    Microbiol Spectr; 2021 Dec; 9(3):e0137621. PubMed ID: 34937195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS Coronavirus-2 Microneutralisation and Commercial Serological Assays Correlated Closely for Some but Not All Enzyme Immunoassays.
    Walker GJ; Naing Z; Ospina Stella A; Yeang M; Caguicla J; Ramachandran V; Isaacs SR; Agapiou D; Bull RA; Stelzer-Braid S; Daly J; Gosbell IB; Hoad VC; Irving DO; Pink JM; Turville S; Kelleher AD; Rawlinson WD
    Viruses; 2021 Feb; 13(2):. PubMed ID: 33557418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2.
    Santiago L; Uranga-Murillo I; Arias M; González-Ramírez AM; Macías-León J; Moreo E; Redrado S; García-García A; Taleb V; Lira-Navarrete E; Hurtado-Guerrero R; Aguilo N; Del Mar Encabo-Berzosa M; Hidalgo S; Galvez EM; Ramirez-Labrada A; de Miguel D; Benito R; Miranda P; Fernández A; Domingo JM; Serrano L; Yuste C; Villanueva-Saz S; Paño-Pardo JR; Pardo J
    Biology (Basel); 2021 Mar; 10(3):. PubMed ID: 33801808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of sample-to-cut-off ratio of anti-SARS-CoV-2 IgG antibody chemiluminescent assay with neutralization activity: a prospective multi-centric study in India.
    Tiwari AK; Negi G; Jaiswal RM; Aggarwal G; Yadav N; Kumar V; Kulathu K
    ISBT Sci Ser; 2021 Nov; 16(4):269-275. PubMed ID: 34548879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History.
    Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF
    Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays.
    Padoan A; Cosma C; Bonfante F; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Pagliari M; Bortolami A; Cattelan A; Cianci V; Basso D; Plebani M
    Clin Chem Lab Med; 2022 Feb; 60(3):456-463. PubMed ID: 34911170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of the Commercial Anti-SARS-CoV-2 Receptor Binding Domain Antibody Test with the Chemiluminescent Reduction Neutralizing Test and Possible Detection of Antibodies to Emerging Variants.
    Morinaga Y; Tani H; Terasaki Y; Nomura S; Kawasuji H; Shimada T; Igarashi E; Saga Y; Yoshida Y; Yasukochi R; Kaneda M; Murai Y; Ueno A; Miyajima Y; Fukui Y; Nagaoka K; Ono C; Matsuura Y; Fujimura T; Ishida Y; Oishi K; Yamamoto Y
    Microbiol Spectr; 2021 Dec; 9(3):e0056021. PubMed ID: 34851163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.